Sandoz Group AG (SWX:SDZ)
41.76
-0.21 (-0.50%)
Feb 21, 2025, 5:31 PM CET
Sandoz Group AG Revenue
Sandoz Group AG had revenue of $5.06B USD in the half year ending June 30, 2024, with 8.28% growth. This brings the company's revenue in the last twelve months to $10.11B, up 5.75% year-over-year. In the year 2023, Sandoz Group AG had annual revenue of $9.98B with 7.23% growth.
Revenue (ttm)
$10.11B
Revenue Growth
+5.75%
P/S Ratio
1.98
Revenue / Employee
$446.74K
Employees
22,633
Market Cap
18.32B CHF
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 9.98B | 673.00M | 7.23% |
Dec 31, 2022 | 9.31B | -372.00M | -3.84% |
Dec 31, 2021 | 9.68B | 20.00M | 0.21% |
Dec 31, 2020 | 9.66B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionSandoz Group AG News
- 6 weeks ago - Intra-Cellular Therapies Stock Soars 19% After Securing Major Patent Victory Over Sandoz - GuruFocus
- 6 weeks ago - Intra-Cellular settles Caplyta patent dispute with Sandoz - Seeking Alpha
- 6 weeks ago - Intra-Cellular Therapies Inc (ITCI) Announces Settlement with Sandoz Over CAPLYTA Patent Litigation - GuruFocus
- 2 months ago - Caplin Point gets USFDA approval for eye drops – Difluprednate Ophthalmic Emulsion - Business Upturn
- 2 months ago - Sandoz Charts Path to Swift Generic Ozempic Launch in Canada - Financial Post
- 2 months ago - Sandoz Charts Path to Swift Generic Ozempic Launch in Canada - BNN Bloomberg
- 3 months ago - Glenmark Pharmaceuticals shares in focus as company launches Travoprost Ophthalmic Solution in U.S. - Business Upturn
- 3 months ago - Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP - Business Upturn